mRECIST Response Combined With Sorafenib-Related Adverse Events Is Superior to Either Criterion Alone in Predicting Survival in HCC Patients Treated With TACE Plus Sorafenib

International Journal of Cancer - United States
doi 10.1002/ijc.30451
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Changing TACTICS in Intermediate HCC: TACE Plus Sorafenib

Gut
Gastroenterology
2020English

Letter: Are Sorafenib-Related Adverse Events Associated With Prolonged Survival? Authors' Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

Sorafenib or Placebo Plus TACE With Doxorubicin-Eluting Beads for Intermediate Stage HCC: The SPACE Trial

Journal of Hepatology
Hepatology
2016English

Sorafenib-Related Adverse Events in Predicting the Early Radiologic Responses of Hepatocellular Carcinoma

Gastroenterology Research
2019English

Early Α-Fetoprotein Response Predicts Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib

Journal of Hepatocellular Carcinoma
2015English

Immortal Time Bias or Sorafenib Effect in Elderly Patients With HCC?

Hepatology
MedicineHepatology
2017English

Multimodality 3D Tumor Segmentation in HCC Patients Treated With TACE

Journal of Vascular and Interventional Radiology
Nuclear MedicineRadiologyCardiologyCardiovascular MedicineImagingMedicine
2015English

Thyroid Dysfunction in Patients Treated With Sunitinib or Sorafenib

Clinical Genitourinary Cancer
OncologyUrology
2012English

The Efficacy of TACE Combined Sorafenib in Advanced Stages Hepatocellullar Carcinoma

BMC Cancer
Cancer ResearchOncologyGenetics
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy